Clinical Trial Update: Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial [Phase 2]

View source ↗

Summary

A Phase II multicenter trial is evaluating the efficacy of a PD-1 inhibitor in combination therapy for non-small cell lung cancer patients who did not achieve a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PD-1 inhibitor (combination therapy)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING